Effects of policosanol and lovastatin in patients with intermittent claudication: A double-blind comparative pilot study

Angiology

Volumn 54, Issue 1, 2003, Pages 25-38

  Castaño, Gladys ^a   Más, Rosa ^b   Fernández, Lilia ^b   Gámez, Rafael ^c   Illnait, José ^b  

^a Medical Surgical Research Center   (Cuba)

^b NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; POLICOSANOL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HEART INFARCTION; HUMAN; INTERMITTENT CLAUDICATION; LIPOPROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREADMILL;

EID: 0037274601     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970305400104     Document Type: Article

References (63)

1. Verhaeghe R: Epidémiologie et pronostic de l'artériopathie oblitérante des membres inférieurs. Drugs 56(suppl 3):1-10, 1998.
2. Balkan B, Vray M, Eschwegp E: Epidemiology of peripheral arterial disease. J Cardiovasc Pharmacol 23(suppl 3):8-16, 1994.
3. Marquis P: Evaluation de l'impact de l'artériopathic oblitérante des membres inferieurs sur la qualité de vie. Drugs 56(suppl 3):25-35, 1998.
4. Criqui M, Langer RD, Fronek A: Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326:381-386, 1992.
5. Dormandy JA, Murray GD: The fate of the claudicant: A prospective study of 1969 claudicants. Eur Vasc Surg 5:131-133, 1991.
6. European Working Group of Critical Leg Ischemia: Second European consensus document on chronic critical leg ischemia. Circulation 84(suppl IV):1-26, 1991.
7. Fowkes FGR, Housley E, Riemersma RA, et al: Smoking, lipids, glucose intolerance and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol. 135:331-340, 1992.
8. Lowe GDO, Fowkes FGR, Dawes J, et al: Blood viscosity, fibrinogen and activation of coagulation and leucocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation 87:1915-1920, 1993.
9. Bowlin SJ, Medalie JH, Flocke SA, et al: Epidemiology of intermittent claudication in middle-aged men. Am J Epidemiol 140:418-430, 1994.
10. Ridker PM, Stampfer MJ, Rifai N: Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a) and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285:2481-2485, 2001.
11. Quick CRG, Cotton LT: The measured effect of stopping smoking on intermittent claudication. Br J Surg 69:S24-S26, 1982.
12. Gardner AW, Poehlman ET: Exercise rehabilitation programs for the treatment claudication pain. A meta-analysis. JAMA 274:975-980, 1995.
13. Reich T, Cutler BS, Lee BY, et al: Pentoxifylline in the treatment of intermittent claudication of the lower limb. Angiology 35:389-393, 1984.
14. Tonnesen KH, Albuquerque P, Baitsch G, et al: Double-blind, controlled multicenter study of indubofen versus placebo in patients with intermittent claudication. Int Angiol 12:371-377, 1993.
15. Lindagarde F, Bjorkman H, Adielsson G, et al, for the Scandinavian Study Group: Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Circulation 80:1549-1556, 1989.
16. Verhaeghe R: Platelets in peripheral arterial disease. Crit Ischaemia 4:21-25, 1994.
17. Pons P, Rodríguez M, Robaina C, et al: Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment. Int J Clin Pharmacol Res 14:27-33, 1994.
18. Canetti M, Morera M, Illnait J, et al: A two-year study on the efficacy and tolerability of policosanol in patients with type II. Int J Clin Pharmacol Res 15:159-165, 1995.
19. Zardoya R, Tula L, Castaño G, et al: Effects of policosanol on hypercholesterolemic patients with disturbances on serum biochemical indicators of hepatic function. Curr Ther Res 57:568-577, 1996.
20. Ortensi G, Gladstein H, Valli H, et al: A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res 58:390-401, 1997.
21. Benítez M, Romero C, Más R, et al: A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia. Curr Ther Res 58:859-867, 1997.
22. Más R, Castaño G, Illnait J, et al: Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 65:439-447, 1998.
23. Castaño G, Más R, Fernández JC, et al: A long-term open study of the efficacy and tolerability of policosanol in patients with high global coronary risk. Curr Ther Res 60:379-391, 1999.
24. Castaño G, Más R, Arruzazabala ML, et al: Effects of policosanol, pravastatin on lipid profile, platelet aggregation, endothelemia in older hypercholesterolemic patients. Int J Clin Pharm Res 19:105-116, 1999.
25. Castaño G, Más R, Fernández L, et al: Effect of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol 13:1-9, 2000.
26. Castaño G, Más R, Fernández JC, et al: Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. J Gerontol (Med Sci) 2000, OJO.
27. Fernández JC, Más R, Castaño G, et al: Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolemic women. Clin Invest 21:103-113, 2001.
28. Torres O, Agramonte AJ, Illnait J, et al: Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 18:393-397, 1995.
29. Crespo N, Alvarez R, Más R, et al: Effect of policosanol on patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia: A pilot study. Curr Ther Res 58:44-51, 1997.
30. Crespo N, Illnait J, Mas R, et al: Comparative study of the efficacy, tolerability of policosanol and lovastatin in patients with hypercholesterolemia and non-insulin-dependent diabetes mellitus. Int J Clin Pharmacol Res 19:105-116, 1999.
31. Arruzazabala ML, Carbajal D, Más R, et al: Effects of policosanol on platelet aggregation in rats. Thromb Res 69:321-327, 1992.
32. Arruzazabala ML, Carbajal D, Molina V, et al: Estudio farmacológico de la interacción entre el policosanol y la aspirina en animales de experimentación. Rev Iberoam Tromb Hemost 5:17-20, 1992.
33. Arruzazabala ML, Valdés S, Más R, et al: Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers. Pharmacol Res 34:181-185, 1996.
34. Scazziota A, Pons S, Altman R: Efecto del policosanol sobre la función de las plaquetas en voluntarios sanos. Rev Iberoam Tromb Hemost 9:58-62, 1996.
35. Carbajal D, Arruzazabala ML, Valdés S, et al: Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers. Prostag Leuk Ess Fatty Acids 58:61-64, 1998.
36. Arruzazabala ML, Valdés S, Más R, et al: Comparative study of policosanol, aspirin and the combination of policosanol-aspirin on platelet aggregation in healthy volunteers. Pharmacol Res 36:293-297, 1997.
37. Menéndez R, Más R, Amor AM, et al: Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Brit J Clin Pharmacol 50:255-262, 2000.
38. Menéndez R, Más R, Amor AM, et al: Effects of policosanol on the susceptibility of low-density lipoprotein isolated from hypercholesterolemic patients at high coronary risk to in vitro copper-mediated lipid peroxidation: A randomized double-bind pilot study. Curr Ther Res 61:609-620, 2000.
39. Noa M, Más R, Mesa R: Effect of policosanol on intimal thickening in rabbit cuffed carotid artery. Intern J Cardiol 67:125-132, 1999.
40. Noa M, Mas R, Mesa R: A comparative study of policosanol versus lovastatin on intimal thickening in rabbit cuffed carotid artery. J Pharmacol Res 2000 (in press).
41. Castaño G, Más R, Fernández L, et al: A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication. Angiology 50:123-130, 1998.
42. Castaño G, Mas R, Fernández L, et al: A long-term study of policosanol in the treatment of intermittent claudication. Angiology 52:115-125, 2001.
43. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994.
44. Sacks FM, Pfeffer MA, Moyé LA, et al, for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009, 1996.
45. Tonkin A, Aylward P, Colqhoun D, et al: Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357, 1998.
46. Shepherd S, Cobbe SM, Ford I, et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301-1307, 1995.
47. Weis S, Clearfield M, Downs JR, et al: The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Primary prevention of acute major coronary events in men and women with average cholesterol. In: Cholesterol-Lowering Therapy: Evaluation of Clinical Evidence, ed. by Grundy S. New York: Marcel Dekker, Inc, 2000, pp 151-172.
48. Farnier M, Davignon J: Current and future treatment of hyperlipidemia; the role of statins. Am J Cardiol 82:3J-10J, 1998.
49. Farnier JA, Gotto AM: Choosing the right lipid-regulating agent: A guide to selection. Drugs 52:649-661, 1996.
50. Wheeler DC: Are there potential non-lipid lowering uses of statins? Drugs 56:517-522, 1998.
51. Corsini A, Pazzucconi F, Arnaboldi L, et al: Direct effects of statins on the vascular wall. J Cardiovasc Pharmacol 31:773-777, 1998.
52. Henwood JM, Heel RC: Lovastatin: A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs 36:429-454, 1988.
53. Illingworth R: Use of lovastatin in the treatment of hypercholesterolemia. Clin Ther 16:2-26, 1994.
54. Iatt WR, Nawaz D, Regensterner JG, et al: The evaluation of exercise performance in patients with peripheral vascular disease. J Cardiopulmonary Rehabil 12:525-532, 1998.
55. Heidrich H, Allenberg J, Cachovan M, et al: Guidelines for therapeutic studies on peripheral arterial occlusive disease in Fontaine stages II-IV. Vasa 21:339-343, 1992.
56. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program (NCEP): Second report of the Expert Panel on Detection. Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). III Drug treatment. Circulation 89:1405-1419; 1432-1445, 1994.
57. Pyorala K, De Backer G, Graham I, et al, on behalf of the Task Force: Prevention of coronary heart disease in clinical practice. Recommendations of the task force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Published simultaneously in Eur Heart J 15:1300-1331 and Atherosclerosis 110:121-161, 1994.
58. Gotto A, Assmann G, Carmena R, et al: The International Lipid Information Bureau (ILIB): Lipid Handbook for Clinical Practice. Blood Lipids and Coronary Heart Disease, ed. 2, 2000.
59. Tofler GH, et al: Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 316:1514-1518, 1987.
60. Schectman G, Hiatt J: Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals. Am J Med 100:197-205, 1996.
61. Seigler L, Wu T: Separation of serum high-density lipoprotein for cholesterol determination: Ultracentrifugation vs precipitation with sodium phosphotungstat and magnesium chloride. Clin Chem 27:838-841, 1981.
62. Friedewald WT, Levy RI, Friederickson SD: Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the preparative ultracentrifuge. Clin Chem 18:499-502, 1972.
63. Fowkes FGR, Leng GC, Lee AJ, et al: The ankle arm index as a predictor of cardiovascular events and death in the general population [abstracts from the 4th International Conference in Preventive Cardiology, 267B]. Can J Cardiol 13(suppl 13), 1997.